Protara Therapeutics, Inc. (NASDAQ:TARA) Holdings Boosted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 40.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 179,125 shares of the company’s stock after purchasing an additional 51,944 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.87% of Protara Therapeutics worth $328,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in TARA. Marshall Wace LLP acquired a new position in Protara Therapeutics during the 2nd quarter valued at approximately $161,000. Renaissance Technologies LLC boosted its holdings in shares of Protara Therapeutics by 77.8% during the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock valued at $313,000 after acquiring an additional 65,800 shares during the period. CVI Holdings LLC bought a new position in shares of Protara Therapeutics during the second quarter worth about $630,000. Ikarian Capital LLC lifted its position in Protara Therapeutics by 7.4% in the 1st quarter. Ikarian Capital LLC now owns 202,701 shares of the company’s stock valued at $813,000 after purchasing an additional 14,037 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Protara Therapeutics in the 2nd quarter valued at about $1,082,000. 38.13% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on TARA shares. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Thursday, November 14th. Oppenheimer cut their target price on Protara Therapeutics from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Monday, August 12th.

Insider Buying and Selling at Protara Therapeutics

In related news, major shareholder Opaleye Management Inc. sold 36,492 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $1.89, for a total transaction of $68,969.88. Following the completion of the sale, the insider now directly owns 54,600 shares of the company’s stock, valued at $103,194. This represents a 40.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is currently owned by corporate insiders.

Protara Therapeutics Stock Down 0.9 %

Shares of TARA opened at $2.29 on Friday. The firm has a market capitalization of $47.24 million, a PE ratio of -0.81 and a beta of 1.77. The firm has a 50-day moving average price of $2.09 and a 200 day moving average price of $2.27. Protara Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). On average, equities analysts expect that Protara Therapeutics, Inc. will post -2.99 EPS for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.